White House Moves to Dump FDA Chief Makary
The White House is preparing to replace Marty Makary, a sign that FDA leadership has become a political liability — and a battlefield over drugs, vaping, and abortion policy.
The White House has signed off on a plan to replace Food and Drug Administration Commissioner Marty Makary after months of agency turmoil and criticism of his decisions, according to 
The Washington Post. 
Bloomberg reported that President Donald Trump plans to fire Makary, though he has not yet been dismissed. The signal is clear: the White House now sees Makary as a drag on control, not an asset.
Why Makary is vulnerable
Makary’s problem is not one scandal but too many fronts. 
STAT said his tenure has been marked by personnel drama, departures, and fights over how aggressively the FDA should move on vaping, abortion pills, and drug review timelines. That has left him squeezed between constituencies that normally pull the agency in opposite directions: White House political operatives want quick wins; industry wants predictability; career scientists want a process that still looks scientific.
That combination is hard to manage because the FDA is not just a health regulator. It is a major power center over drugs, vaccines, food rules, and politically sensitive culture-war issues. When Makary hesitated on flavored vapes, pushed slower reviews on some products, or drew conservative anger over the abortion pill mifepristone, he was not merely disappointing interest groups — he was creating a succession of vetoes from the right, the pharmaceutical industry, and parts of his own bureaucracy.
The real leverage is inside HHS
The deeper story is that the administration now has leverage over Makary because the FDA’s instability has become operationally costly. STAT said the move would add yet another vacancy in Robert F. Kennedy Jr.’s health department, which still lacks permanent leadership in other top posts. 
CNN has also described the FDA as already suffering from churn in its vaccine and biologics leadership, with major decisions drawing internal and external backlash.
That matters because personnel control is policy control. If the White House wants faster approvals, different standards, or more visible action on politically favored issues, it needs a commissioner who will execute, not resist. Replacing Makary is therefore not just a personnel move; it is an attempt to reset the FDA’s decision-making chain before the next round of fights over drugs, vaccines, and food policy. For 
Global Politics, this is a reminder that domestic agencies can become pressure points in presidential power contests.
What to watch next
The next decision point is whether Trump formally removes Makary or forces a resignation and names an acting successor. Watch for two things: first, whether the White House picks a figure acceptable to Kennedy’s camp and Senate Republicans; second, whether the choice signals a harder political turn on FDA approvals, especially vaping and mifepristone. A new commissioner will still need Senate confirmation, which gives the White House a stopgap but also exposes how much internal disagreement remains. For the United States, the key question is whether this becomes a cleanup operation — or the start of another leadership purge at HHS.
